Catalyst Pharmaceuticals (CPRX) Enterprise Value (2016 - 2025)
Catalyst Pharmaceuticals (CPRX) has disclosed Enterprise Value for 16 consecutive years, with -$709.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 37.02% year-over-year to -$709.2 million, compared with a TTM value of -$709.2 million through Dec 2025, down 37.02%, and an annual FY2025 reading of -$709.2 million, down 37.02% over the prior year.
- Enterprise Value was -$709.2 million for Q4 2025 at Catalyst Pharmaceuticals, down from -$689.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$121.0 million in Q3 2023 and bottomed at -$709.2 million in Q4 2025.
- Average Enterprise Value over 5 years is -$323.8 million, with a median of -$233.5 million recorded in 2022.
- The sharpest move saw Enterprise Value skyrocketed 53.87% in 2023, then tumbled 276.03% in 2024.
- Year by year, Enterprise Value stood at -$191.3 million in 2021, then plummeted by 56.01% to -$298.4 million in 2022, then surged by 53.87% to -$137.6 million in 2023, then crashed by 276.03% to -$517.6 million in 2024, then tumbled by 37.02% to -$709.2 million in 2025.
- Business Quant data shows Enterprise Value for CPRX at -$709.2 million in Q4 2025, -$689.9 million in Q3 2025, and -$652.8 million in Q2 2025.